New Salese lozenges look to ease symptoms of those who suffer dry mouth
Santa Clara, Calif. — Nuvora Inc. announced today the availability of a new soft lozenge to help provide relief for those who suffer from dry mouth.
Salese is a sugar-free and alcohol-free lozenge with Nuvora’s patented SuRe (sustained release) delivery system, which enables the lozenge to relieve dry mouth for one hour or longer, the company stated. The SuRe technology allows the lozenge to dissolve slower and release active ingredients at a more sustained rate than such traditional dry mouth products as toothpastes, mouthwash and chewing gum, which may last only minutes, the company said. The technology is designed to also neutralize acid pH levels, killing 99.9% of bacteria and helping to eliminate germs that may cause bad breath.
Dry mouth is caused by a lack of saliva production, which can occur as a side effect of numerous prescription and over-the-counter medications for pain, allergies, Parkinson’s, Alzheimer’s and diabetes, as well as a symptom of Sjoren’s Syndrome and Lupus, the company stated. Dry mouth is also common in cancer patients undergoing radiation therapy around the head and neck. Drinking plenty of water, chewing sugar-free gum or sucking on sugar-free hard candy are helpful ways to stimulate saliva production, but may be short lived, the company stated.
“For someone who suffers from dry mouth on a daily basis, a few minutes of relief just isn’t enough,” explains Bolko Stolberg, EVP of Nuvora Inc., creator of Salese. “With this unique patented technology, we can now offer longer lasting relief to not only provide comfort to dry mouth sufferers but to improve the overall health of the mouth and gums — helping to combat tooth decay, inflammations and other serious oral infections from developing.”
Salese’s key ingredients include Xanthan gum — which locks in moisture — essential oils and Xylitol that help to destroy bacteria and prevent tooth decay, sodium bicarbonate to help neutralize pH levels to protect tooth enamel and zinc to prevent bad breath.
Salese is available for $5.99 in peppermint and wintergreen flavors at DrugStore.com, Walgreens.com and ShopRite.
Get connected and follow us on LinkedIn for the most in-depth coverage of drug store news. Join the conversation.
Consumer Goods Forum appoints Ahold CEO as co-chairman
AMSTERDAM — An industry network of 400 retailers, manufacturers and other companies has appointed the head of Dutch supermarket operator Royal Ahold to an executive position.
The Consumer Goods Forum announced Wednesday the appointment of Ahold CEO Dick Boer as co-chairman following the meeting of its board of directors in Tokyo. The other co-chairman is Nestle CEO Paul Bulcke, and the two will replace outgoing chairman Muhtar Kent, chairman and CEO of the Coca-Cola Co., and Gareth Ackerman, chairman of Pick ‘n’ Pay. The board of the CGF, a group founded in 2009, comprises 50 leaders of retail and manufacturing companies.
"Ahold has been working with the CGF for many years, and we are honored to be involved at such a high level now," Boer said. "The CGF is uniquely positioned to drive the vision of the industry and encourage real change. Its ability to bring companies together for the good of our customers makes the work of the CGF both relevant and important."
Study: Retail clinics to double, save $800M annually by 2015
LAS VEGAS — The number of U.S. retail health clinics is projected to double by 2015 because of the increasing demand of newly insured patients under healthcare reform, according to new a report released on Wednesday by Accenture ACN at the annual America’s Health Insurance Plans Institute 2013 conference in Las Vegas.
The report shows that the growing number of retail-based health clinics is expected to drive $800 million in annual cost savings by 2015 and will add capacity for 10.8 million patient visits per year, compared with 5.1 million in 2011. In fact, according to Accenture’s analysis, the number of patient visits at retail clinics is projected to account for 10% of non-primary care outpatient visits by the end of 2015.
"Despite that initial growth of retail clinics was halted short of market expectations in 2009, healthcare reform will trigger a significant demand from millions of newly insured patients," Kaveh Safavi, managing director for Accenture’s North America health business, said. "The convergence of retail convenience with walk-in care services will provide a ‘release valve’ for strained health systems as they handle the influx of new patients."
Historically, retail clinics experienced a five-year trend of rapid growth from 2003 to 2008, ranging from 50% to 92% annually during that time. However, growth in the sector stalled, falling to just 2% per year, from 2008 to 2012, the report stated.
According to Accenture’s report, the number of retail clinics is expected to increase 20% to 25% per year between now and 2015 and double from 1,418 to 2,868 clinics in that time period.
"Although primary care physicians and hospitals once regarded retail clinics as a business threat, in a post-reform landscape, they are viewed as critical to facilitating future growth," Safavi added. "In fact, retail clinics will reduce capacity constraints by referring lower-acuity patients to clinics while ensuring hospitals have capacity for more complex cases."